Niagen Bioscience, Inc. (NASDAQ: NAGE) has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. In this role, Dr. Kale will oversee the company's worldwide network of academic and clinical research collaborations and help shape its scientific research strategy.

Dr. Kale brings more than a decade of experience in aging biology, translational science, and external scientific partnerships. Most recently, he served as a Scientific Review Officer at Hevolution Foundation, where he evaluated more than 600 research proposals and contributed funding recommendations across a $1 billion global longevity research portfolio. He has also held scientific leadership roles at the Buck Institute for Research on Aging, Deciduous Therapeutics, and LevitasBio. Dr. Kale earned his Ph.D. in Molecular Genetics from Albert Einstein College of Medicine and has authored 16 publications, including research on NAD+ biology and aging.

"Science informs our strategy and our messaging, not the other way around," said Rob Fried, CEO of Niagen Bioscience. "We are excited for Abhijit to help deepen our collaborations with leading researchers worldwide and further advance our understanding of the fascinating science of NAD+."

Dr. Kale will lead the company's Niagen Research Program, which the company states supports more than 175 ongoing and developing research studies, with more than 45 peer-reviewed published clinical studies on its nicotinamide riboside ingredient, Niagen. Institutions including Mayo Clinic, the National Institutes of Health, Harvard University, MIT, and Cambridge University have participated in the program.

Under Dr. Kale's leadership, Niagen Bioscience said it plans to expand the program into areas including pharmaceutical-grade Niagen injections and infusions, topical applications, and research on other NAD+ precursors.